title: [Recurrent neutrophilic panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib mesilate and dasatinib].
abstract: BACKGROUND
  Tyrosine kinase inhibitors are now established as valuable therapy in chronic myelogenous leukaemia (CML). They induce several types of cutaneous side effect, the most common being non-specific maculopapular rash and periocular oedema. Rare cases of panniculitis have been described in patients with CML treated with imatinib mesilate and dasatinib. We report a case of recurrent panniculitis in a patient with CML treated successively with imatinib mesilate and dasatinib.
  
  
  METHODS
  An 81-year-old woman diagnosed with chronic CML experienced two episodes of neutrophilic panniculitis following imatinib mesilate therapy, as well as relapse following replacement of imatinib mesilate by dasatinib. Several skin biopsies showed a neutrophilic infiltrate throughout the fatty tissue lobules, without vasculitis and without any evidence of bacterial infection. The symptoms gradually subsided without discontinuation of tyrosine kinase inhibitor therapy.
  
  
  CONCLUSIONS
  Neutrophilic panniculitis is uncommon among patients treated with tyrosine kinase inhibitors and has only been described in patients treated for chronic myeloid leukaemia. We discuss the potential causative role of imatinib mesilate and dasatinib in onset of the disease, as well as differential diagnosis of neutrophilic panniculitis, which resembles subcutaneous Sweet's syndrome.
authors.affiliation: Research unit EA 4339 skin, cancer, and environment, service de dermatologie générale et oncologique, Faculty of medicine Paris-Ile-de-France Ouest, CHU A.-Paré, University of Versailles-SQY, 92104 Boulogne cedex, France. adele.de.masson@hotmail.fr
authors.forename: A
authors.initials: A
authors.lastname: de Masson
authors.forename: S
authors.initials: S
authors.lastname: Bouvresse
authors.forename: T
authors.initials: T
authors.lastname: Clérici
authors.forename: E
authors.initials: E
authors.lastname: Mahé
authors.forename: P
authors.initials: P
authors.lastname: Saïag
mesh_terms: D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use / Q000633:toxicity*; D001549:Benzamides; D001706:Biopsy; D000069439:Dasatinib; D003875:Drug Eruptions / Q000175:diagnosis* / Q000473:pathology; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D009504:Neutrophils / Q000187:drug effects* / Q000473:pathology; D015434:Panniculitis / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D010879:Piperazines / Q000008:administration & dosage / Q000633:toxicity*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000633:toxicity*; D011743:Pyrimidines / Q000008:administration & dosage / Q000633:toxicity*; D012008:Recurrence; D012867:Skin / Q000187:drug effects / Q000473:pathology; D013844:Thiazoles / Q000008:administration & dosage / Q000633:toxicity*
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D000069439:Dasatinib